Atsena Therapeutics

VISIONS 2024, the global conference of the Foundation Fighting Blindness, brought together individuals and families from all over the world who are affected by blinding diseases. Kenji Fujita, our Chief Medical Officer, and Kara Fick, our Director of Patient Advocacy and Medical Affairs, had the pleasure of attending VISIONS to engage with the #LowVision community and meet inspiring families. It was an honor to be part of an event that closely aligns with Atsena’s mission to improve the quality of life of patients with #InheritedRetinalDisease. Image description: Text on the top reads “Atsena at Foundation Fighting Blindness VISIONS ’24.” On the left, Kara Fick and Kenji Fujita are standing at Atsena’s booth. In the middle, a sign at the conference details the session in which Kenji Fujita spoke, “Concurrent Science Session: Gene Therapy and Genome Editing.” On the right, Kenji Fujita is speaking into a microphone. The Atsena Therapeutics logo is in the bottom right corner. 

Our Chief Medical Officer Kenji Fujita, MD, had the pleasure of speaking with Tyler Menichiello about the rise of gene therapies being developed for #InheritedRetinalDiseases and Atsena’s clinical programs in #LCA1 and #XLRS. Check out the article in Cell & Gene. ⬇ #GeneTherapy #ophthalmology

The last week of June is DeafBlind Awareness Week, a time to increase understanding of the challenges and celebrate the accomplishments of individuals who have combined vision and hearing loss. Visit the website of Helen Keller Services for inspiring stories of individuals who are #DeafBlind: https://lnkd.in/erPmuf8v. #DBAW Image description: Purple and blue background on the left with text that reads, “Atsena Recognizes DeafBlind Awareness Week.” An image of tactile sign language is on the right. The Atsena Therapeutics logo is in the bottom right corner. 

VISIONS 2024, the global conference of the Foundation Fighting Blindness, is just a few days away! We can’t wait to head to Chicago to connect with the #blind and #LowVision community. If you’re attending VISIONS 2024, be sure to stop by our Atsena Therapeutics booth and say hello! Also, don’t miss Kenji Fujita, our Chief Medical Officer, speak about #GeneTherapy on Friday, June 21 at 10:30 a.m.   Atsena is pleased to be a sponsor of this informative conference designed specifically for individuals and families affected by blinding diseases. For more information about VISIONS 2024, visit: https://lnkd.in/eYcJHe3F Image description: Purple and teal background with text that reads “Foundation Fighting Blindness” above the VISIONS 2024 logo. Text underneath the logo reads “June 21-22, 2024, Chicago.” The Atsena Therapeutics logo is in the bottom right corner. 

At Atsena, we’re focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. From participating in the Triangle VisionWalk to sharing research on #XLRS, #LCA1 and #GeneTherapy technology at industry conferences, we enjoy engaging with the ocular gene therapy community and spending time with our fellow Atsenians. To learn more about what we do at Atsena and our dedication to addressing the needs of patients with vision loss, visit https://atsenatx.com/. #ARVO2024 #ASGCT2024 #ophthalmology Image description: On the top left is Joanna Robbie, Laura Pardon, OD, PhD, FAAO, Canaan Coppola, and Bryan Troxell wearing t-shirts with the Atsena Therapeutics logo and standing in front of a VisionWalk flag. On the top right is Dan Yoon, Laura Pardon, Shannon Boye, and Kenji Fujita standing in front of a podium at ARVO 2024. On the bottom left is Shannon Boye, Patrick Ritschel, Sanford Boye and Eva Andres-Mateos in Baltimore. On the bottom right is Shannon Boye speaking behind a podium at the ASGCT 27th Annual Meeting. The Atsena Therapeutics logo is in the bottom right corner. 

The third Thursday of each May is Global Accessibility Awareness Day (#GAAD), a day to recognize the importance of digital access and #inclusion for people with disabilities and impairments.   Did you know that including alternative (alt) text for images on the web makes content more accessible for people with visual impairments?   For a list of #accessibility features, technology, tools, and learning resources, visit https://lnkd.in/dF9VHUzJ.   Image description: Text says “Atsena Recognizes Global Accessibility Awareness Day, May 16, 2024.” The GAAD logo is on the left. A white banner stretches across the bottom with the Atsena Therapeutics logo in the right corner.

We’re looking forward to joining our peers and hearing the latest #GeneTherapy research at the ASGCT 27th Annual Meeting!   Don’t miss Shannon Boye, our Founder and Director, share valuable insights during two Scientific Symposium sessions at #ASGCT2024:   Friday, May 10 You Have a Great Technology...Now What? (Organized by the New Investigator Committee) Room 339-342 Dr. Boye’s presentation will begin at 1:40 p.m.   Saturday, May 11 Recent Advancements That Expand Viral Vector Delivery Applications (Organized by the Viral Gene Transfer Vectors Committee) Ballroom 1 Dr. Boye’s presentation will begin at 9:18 a.m.   Image description: A photo of the Baltimore waterfront is in the background. Text on the left says, “See you in Baltimore at the ASGCT 27th Annual Meeting, May 7-11.” The Atsena Therapeutics logo is in the top right corner.

Are you heading to Seattle for the Retinal Cell and Gene Therapy Innovation Summit 2024 and the ARVO 2024 Annual Meeting? We are!   On Friday, May 3rd at the Retinal Cell and Gene Therapy Innovation Summit, our Founder and Director Shannon Boye will speak about the IND-enabling studies supporting the clinical development of our investigational #GeneTherapy ATSN-201, which utilizes our novel spreading capsid AAV.SPR. Additionally, our Clinical Ophthalmology Advisor Christine Kay will present preliminary safety data from the ongoing Phase I/II clinical trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (#XLRS).   On Sunday, May 5th during a symposium at #ARVO2024, Dr. Boye will speak about the safety and efficacy of our investigational gene therapy ATSN-101 in patients with #LeberCongenitalAmaurosis caused by biallelic mutations in GUCY2D (#LCA1).     We hope to see you in Seattle!   Image description: A photo of the Seattle skyline is in the background. Text on the right says, “Connect with us in Seattle, Retinal Cell and Gene Therapy Innovation Summit, May 3, ARVO Annual Meeting, May 5-9.” The Atsena Therapeutics logo is in the top right corner.  

We are excited to share data from the first cohort of the LIGHTHOUSE study, our ongoing Phase I/II clinical trial evaluating our investigational #GeneTherapy ATSN-201 for the treatment of X-linked retinoschisis (#XLRS). For the first time in patients, we have validated the ability of AAV.SPR, our novel spreading #capsid, to spread laterally well beyond the subretinal injection blebs. Additionally, we have demonstrated the ability to safely administer subretinal injections in patients with extensive retinal schisis. Subretinal injection of ATSN-201 was well tolerated in all three patients in the first cohort with two patients showing extensive resolution of schisis beginning at 8 weeks after dosing. Additional and continued resolution of schisis was observed through week 24, the latest time point available. Read more about the data in our press release: https://lnkd.in/eAcpdUHS

One of the first signs of X-linked retinoschisis (#XLRS) is loss of visual acuity that cannot be corrected with glasses. This vision loss, which is due to splitting of the layers of the retina, is progressive and can lead to blindness.   To learn more about XLRS and our ongoing clinical program, visit https://lnkd.in/grzEZVMt.   #InheritedRetinalDisease #GeneTherapy   Image description: On the top left is a lightbulb next to text that says “Did You Know?” Text underneath says “One of the first signs of X-linked retinoschisis (XLRS) is loss of visual acuity that isn't correctable with glasses.” A photo of a boy reading a graphic novel is on the right. A white banner stretches across the bottom with the Atsena Therapeutics logo in the right corner.